methylphenidate has been researched along with Obesity in 31 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to examine sex differences in response to a single dose of a psychomotor-stimulant medication (methylphenidate: MP) and to assess whether expected differences were moderated by binge-eating disorder (BED) status." | 9.22 | Sex differences in subjective and objective responses to a stimulant medication (methylphenidate): Comparisons between overweight/obese adults with and without binge-eating disorder. ( Carter-Major, JC; Davis, C; Kaplan, AS; Kennedy, JL; Levitan, RD, 2016) |
| "A retrospective analysis included children with a history of brain tumor and hypothalamic obesity receiving methylphenidate (10-60 mg/day) for hypothalamic obesity." | 7.96 | Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. ( Bielamowicz, K; Hilsenbeck, S; Horne, VE; Lindsay, H; Nguyen, J; Okcu, F; Sisley, S; Sonabend, R; Wood, AC, 2020) |
| "The purpose of this study was to examine sex differences in response to a single dose of a psychomotor-stimulant medication (methylphenidate: MP) and to assess whether expected differences were moderated by binge-eating disorder (BED) status." | 5.22 | Sex differences in subjective and objective responses to a stimulant medication (methylphenidate): Comparisons between overweight/obese adults with and without binge-eating disorder. ( Carter-Major, JC; Davis, C; Kaplan, AS; Kennedy, JL; Levitan, RD, 2016) |
| " Obese patients (n = 101) were randomized in a 1:2:2 ratio to either (i) standard nutrition counselling; or (ii) the Department of Veterans Affairs weight loss programme called 'motivate obese veterans everywhere ' (MOVE); or (iii) methylphenidate treatment plus the MOVE programme together." | 5.16 | Role of apathy in the effectiveness of weight management programmes. ( Anzures, P; Demasi, C; Desouza, CV; Haynatzki, G; Padala, PR; Shivaswamy, V, 2012) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| "A retrospective analysis included children with a history of brain tumor and hypothalamic obesity receiving methylphenidate (10-60 mg/day) for hypothalamic obesity." | 3.96 | Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. ( Bielamowicz, K; Hilsenbeck, S; Horne, VE; Lindsay, H; Nguyen, J; Okcu, F; Sisley, S; Sonabend, R; Wood, AC, 2020) |
| " By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level." | 2.64 | Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. ( Akpinar, S; Herrmann, WM; Itil, TM, 1975) |
| "Obesity is a major public health problem." | 2.41 | The role of dopamine in motivation for food in humans: implications for obesity. ( Fowler, JS; Volkow, ND; Wang, GJ, 2002) |
| "Increased research focusing on the eating disorders has put the clinician on firmer ground when choosing appropriate psychopharmacologic treatments." | 2.37 | Pharmacologic treatment of eating disorders. ( Gwirtsman, H; Jimerson, DC; Kaye, W; Weintraub, M, 1984) |
| "Methylphenidate did not increase 24-h heart rates, whereas omega-3 fatty acid supplementation significantly decreased elevated heart rates and increased HRV in adolescents with IST." | 1.56 | Diagnosis and management of an inappropriate sinus tachycardia in adolescence based upon a Holter ECG: A retrospective analysis of 479 patients. ( Baumann, C; Buchhorn, R; Gündogdu, S; Rakowski, U; Willaschek, C, 2020) |
| "Methylphenidate treatment did not significantly affect height, weight, or overweight status." | 1.37 | Body mass index of children with attention-deficit/hyperactivity disorder. ( Berger, I; Dubnov-Raz, G; Perry, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (45.16) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (16.13) | 29.6817 |
| 2010's | 10 (32.26) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Horne, VE | 1 |
| Bielamowicz, K | 1 |
| Nguyen, J | 1 |
| Hilsenbeck, S | 1 |
| Lindsay, H | 1 |
| Sonabend, R | 1 |
| Wood, AC | 1 |
| Okcu, F | 1 |
| Sisley, S | 1 |
| Buchhorn, R | 1 |
| Baumann, C | 1 |
| Gündogdu, S | 1 |
| Rakowski, U | 1 |
| Willaschek, C | 1 |
| Anagnostou, E | 1 |
| Granato, MF | 1 |
| Ferraro, AA | 1 |
| Lellis, DM | 1 |
| Casella, EB | 1 |
| Aguilar, AC | 1 |
| Brant, PHRC | 1 |
| Tufik, S | 1 |
| Coelho, FM | 1 |
| Danilovich, N | 1 |
| Mastrandrea, LD | 1 |
| Cataldi, L | 1 |
| Quattrin, T | 1 |
| Davis, C | 2 |
| Levitan, RD | 2 |
| Kaplan, AS | 2 |
| Carter-Major, JC | 1 |
| Kennedy, JL | 2 |
| Findling, RL | 1 |
| Nymark, TB | 1 |
| Hovland, A | 1 |
| Bjørnstad, H | 1 |
| Nielsen, EW | 1 |
| Wagner, KD | 1 |
| Dubnov-Raz, G | 1 |
| Perry, A | 1 |
| Berger, I | 1 |
| Albayrak, O | 1 |
| Albrecht, B | 1 |
| Scherag, S | 1 |
| Barth, N | 1 |
| Hinney, A | 1 |
| Hebebrand, J | 1 |
| Wang, GJ | 2 |
| Geliebter, A | 1 |
| Volkow, ND | 2 |
| Telang, FW | 1 |
| Logan, J | 1 |
| Jayne, MC | 1 |
| Galanti, K | 1 |
| Selig, PA | 1 |
| Han, H | 1 |
| Zhu, W | 1 |
| Wong, CT | 1 |
| Fowler, JS | 2 |
| Fattore, L | 1 |
| Carter, JC | 1 |
| Desouza, CV | 1 |
| Padala, PR | 1 |
| Haynatzki, G | 1 |
| Anzures, P | 1 |
| Demasi, C | 1 |
| Shivaswamy, V | 1 |
| FITZGERALD, O | 1 |
| McELEARNEY, LG | 1 |
| GUILLON, A | 1 |
| BENKHOUCHA, M | 1 |
| BRET, AJ | 1 |
| SIMON, S | 1 |
| ROBERTS, HJ | 2 |
| SOURS, JA | 1 |
| SINISI, C | 1 |
| LEPRAT, J | 1 |
| Leddy, JJ | 1 |
| Epstein, LH | 1 |
| Jaroni, JL | 1 |
| Roemmich, JN | 1 |
| Paluch, RA | 1 |
| Goldfield, GS | 1 |
| Lerman, C | 1 |
| Gwirtsman, H | 1 |
| Kaye, W | 1 |
| Weintraub, M | 1 |
| Jimerson, DC | 1 |
| Antelman, SM | 1 |
| Caggiula, AR | 1 |
| Black, CA | 1 |
| Edwards, DJ | 1 |
| Itil, TM | 1 |
| Herrmann, WM | 1 |
| Akpinar, S | 1 |
| Kreze, A | 1 |
| Toman, A | 1 |
| Ladewig, D | 1 |
| Battegay, R | 1 |
5 reviews available for methylphenidate and Obesity
| Article | Year |
|---|---|
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
The role of dopamine in motivation for food in humans: implications for obesity.
Topics: Animals; Appetite; Brain Chemistry; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Antagonis | 2002 |
NARCOLEPSY AND OTHER DISTURBANCES IN THE SLEEP-WAKING RHYTHM: A STUDY OF 115 CASES WITH REVIEW OF THE LITERATURE.
Topics: Black People; Cataplexy; Craniocerebral Trauma; Depression; Dextroamphetamine; Encephalitis; Halluci | 1963 |
Pharmacologic treatment of eating disorders.
Topics: Anorexia Nervosa; Anticonvulsants; Antidepressive Agents; Antidepressive Agents, Tricyclic; Central | 1984 |
6 trials available for methylphenidate and Obesity
| Article | Year |
|---|---|
Methylphenidate decreases fat and carbohydrate intake in obese teenagers.
Topics: Adolescent; Black or African American; Body Mass Index; Child; Dietary Carbohydrates; Dietary Fats; | 2014 |
Sex differences in subjective and objective responses to a stimulant medication (methylphenidate): Comparisons between overweight/obese adults with and without binge-eating disorder.
Topics: Adult; Affect; Appetite; Binge-Eating Disorder; Central Nervous System Stimulants; Cross-Over Studie | 2016 |
Enhanced striatal dopamine release during food stimulation in binge eating disorder.
Topics: Adult; Binge-Eating Disorder; Body Mass Index; Corpus Striatum; Dopamine; Eating; Energy Intake; Foo | 2011 |
Role of apathy in the effectiveness of weight management programmes.
Topics: Apathy; Central Nervous System Stimulants; Directive Counseling; Female; Humans; Male; Methylphenida | 2012 |
Influence of methylphenidate on eating in obese men.
Topics: Adult; Cross-Over Studies; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Double-Blin | 2004 |
Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram.
Topics: Adolescent; Adult; Aged; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
20 other studies available for methylphenidate and Obesity
| Article | Year |
|---|---|
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity.
Topics: Brain Neoplasms; Cancer Survivors; Central Nervous System Stimulants; Child; Child, Preschool; Femal | 2020 |
Diagnosis and management of an inappropriate sinus tachycardia in adolescence based upon a Holter ECG: A retrospective analysis of 479 patients.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Electrocardiography, Ambulatory; Fatty Ac | 2020 |
Associations between Attention-Deficit Hyperactivity Disorder (ADHD) Treatment and Patient Nutritional Status and Height.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Brazil; Cen | 2018 |
Finding a needle in the haystack-narcolepsy and obstructive sleep apnea.
Topics: Adult; Cephalometry; Diagnosis, Differential; Disorders of Excessive Somnolence; Humans; Male; Methy | 2019 |
A young man with acute dilated cardiomyopathy associated with methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cardiomyopathy, Dilated; Central Nervous | 2008 |
Recognizing parents' symptoms, obesity, and bipolar depression.
Topics: Adolescent; Age Factors; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2008 |
Body mass index of children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Mass Index; Central Nervous System S | 2011 |
Successful methylphenidate treatment of early onset extreme obesity in a child with a melanocortin-4 receptor gene mutation and attention deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child, Preschool; Humans; Male; Methylphenidate; Muta | 2011 |
The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults.
Topics: Adult; Appetite Depressants; Body Weight; Central Nervous System Stimulants; Eating; Female; Humans; | 2012 |
Clinical trial of cafilon and ritalin in the treatment of obesity.
Topics: Central Nervous System Stimulants; Drug Combinations; Humans; Methylphenidate; Obesity; Phenmetrazin | 1957 |
[Apropos of slimming cures by RP-8,228 in a psychiatric hospital].
Topics: Appetite; Hospitals, Psychiatric; Methylphenidate; Obesity | 1962 |
[Obesity in pregnancy. Trial of RP 8228. 1-Phenyl-1-(2-piperidyl)-1-acetoxymethane HCi. Threolevogyric form].
Topics: Female; Humans; Methylphenidate; Obesity; Pregnancy; Pregnancy Complications | 1963 |
THE SYNDROME OF NARCOLEPSY AND DIABETOGENIC (FUNCTIONAL) HYPERINSULINISM. OBSERVATIONS ON 190 PATIENTS, WITH EMPHASIS UPON ITS RELATIONSHIP TO OBESITY, DIABETES MELLITUS AND CEREBRAL DYSRHYTHMIAS.
Topics: Adolescent; Alcoholism; Arrhythmias, Cardiac; Brain; Diabetes Mellitus; Diet; Diet, Reducing; Electr | 1963 |
[ON THE PICKWICK SYNDROME AND ITS DISTURBANCES OF A NARCOLEPTIC TYPE].
Topics: Carbon Dioxide; Diagnosis, Differential; Diet; Diet Therapy; Diuretics; Electroencephalography; Huma | 1963 |
THE SYNDROME OF NARCOLEPSY AND DIABETOGENIC ("FUNCTIONAL") HYPERINSULINISM, WITH SPECIAL REFERENCE TO OBESITY, DIABETES, IDIOPATHIC EDEMA, CEREBRAL DYSRHYTHMIAS AND MULTIPLE SCLEROSIS (200 PATIENTS).
Topics: Alcoholism; Arrhythmias, Cardiac; Cerebrovascular Disorders; Diabetes Mellitus; Drug Therapy; Edema; | 1964 |
[The value of phacetoperan in the treatment of obesity].
Topics: Methylphenidate; Obesity | 1962 |
Stress reverse the anorexia induced by amphetamine and methylphenidate but not fenfluramine.
Topics: Animals; Anorexia; Dextroamphetamine; Dose-Response Relationship, Drug; Feeding and Eating Disorders | 1978 |
[Therapeutic effect of various appetite depressants under controlled conditions].
Topics: Adult; Appetite Depressants; Body Weight; Chlorphentermine; Female; Humans; Methylphenidate; Obesity | 1973 |
Abuse of anorexics with special reference to newer substances.
Topics: Adolescent; Adult; Amines; Amphetamine; Appetite Depressants; Female; Humans; Methamphetamine; Methy | 1971 |
Drugs for depression.
Topics: Amphetamine; Antidepressive Agents; Humans; Methylphenidate; Monoamine Oxidase Inhibitors; Obesity; | 1968 |